Agios Pharmaceuticals Reports Q2 2026 Results

What Happened
On July 30, 2026, Agios Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 via a press release, which the company furnished as Exhibit 99.1 to a Form 8-K filed the same day. The Form 8-K (Item 2.02) discloses the company’s reported quarterly results and other business highlights; the filing is signed by CEO Brian Goff. The company notes the press release is “furnished” (not “filed”) and therefore is not subject to Section 18 liability or automatically incorporated by reference in other filings.

Key Details

• Filing date: July 30, 2026 (Form 8-K reporting results for quarter ended June 30, 2026).
• Item reported: 2.02 — Results of Operations and Financial Condition; press release furnished as Exhibit 99.1.
• Exhibits listed: Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page).
• Signature: Form 8-K signed by Brian Goff, Chief Executive Officer.

Why It Matters
This filing signals that Agios has released its quarterly earnings and business updates — key information investors use to evaluate recent revenue, earnings, and operational progress. Because the press release is furnished rather than filed, it is provided for disclosure but is not treated as “filed” under Section 18 of the Exchange Act. Retail investors should read the furnished press release (and any subsequent 10-Q or related SEC filings) for the specific financial metrics, guidance or pipeline news that could affect the company’s outlook and stock performance.